Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Millions of people around the world are deemed to be at high risk of contracting the human immunodeficiency virus (HIV). But only ... Concentrations of the annual medication remain in the body ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...